HANDOK Inc.
KSE 002390.KS
HANDOK Inc. Free Cash Flow for the year ending December 31, 2023: USD 7.53 M
-
HANDOK Inc. Free Cash Flow for the year ending December 31, 2022 was USD -10.44 M, a -100.28% change year over year.
-
HANDOK Inc. Free Cash Flow for the year ending December 31, 2021 was USD -5.21 M, a -439.23% change year over year.
-
HANDOK Inc. Free Cash Flow for the year ending December 31, 2020 was USD 1.54 M, a 110.35% change year over year.
-
HANDOK Inc. Free Cash Flow for the year ending December 31, 2019 was USD -14.85 M, a -311.22% change year over year.
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
| CEO | Mr. Young-Jin Kim M.B.A. |
| IPO Date | Jan. 4, 2000 |
| Location | South Korea |
| Headquarters | 132 Teheran-ro |
| Employees | 938 |
| Sector | Health Care |
| Industries | |
Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
Past 5 years
USD 68.20
USD 89.21
USD 32.09
USD 4.37
USD 16.03
StockViz Staff
January 15, 2025
Any question? Send us an email